|
1
|
Clark GM, Sledge GW Jr, Osborne CK and
McGuire WL: Survival from first recurrence: relative importance of
prognostic factors in 1,015 breast cancer patients. J Clin Oncol.
5:55–61. 1987.PubMed/NCBI
|
|
2
|
Greenberg PA, Hortobagyi GN, Smith TL,
Ziegler LD, Frye DK and Budzar AU: Long-term follow-up of patients
with complete remission following combination chemotherapy for
metastatic breast cancer. J Clin Oncol. 14:2197–2205.
1996.PubMed/NCBI
|
|
3
|
Launchbury AP and Habbubi N: Epirubicin
and doxorubicin: a comparison of their characteristics, therapeutic
activity and toxicity. Cancer Treat Rev. 3:197–228. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Smith LA, Cornelius VR, Plummer CJ, Levitt
G, Verrill M, Canney P and Jones A: Cardio-toxicity of
anthracycline agents for the treatment of cancer: systematic review
and meta-analysis of randomized controlled trials. BMC Cancer.
10:3372010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Von Hoff DD, Layard MW, Basa P, et al:
Risk factors for doxorubicin-induced congestive heart failure. Ann
Intern Med. 91:710–717. 1979.PubMed/NCBI
|
|
6
|
Bristow MR: Anthracycline cardio-toxicity.
Drug-Induced Heart Disease. Elsevier; New York: pp. 191–215.
1980
|
|
7
|
Jackson JA, Reeves JP, Muntz KH, et al:
Evaluation of free radical effects and catecholamine alterations in
adriamycin cardio-toxicity. Am J Pathol. 117:140–153.
1984.PubMed/NCBI
|
|
8
|
Rajagopalan S, Politi PM, Sinha BK, et al:
Adriamycin induced free radical formation in the perfused rat
heart: implications for cardio-toxicity. Cancer Res. 48:4766–4769.
1988.PubMed/NCBI
|
|
9
|
Myers CE, McGuire WP, Liss RH, et al:
Adriamycin: the role of lipid peroxidation in cardiac toxicity and
tumor response. Science. 197:165–167. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Steinherz LJ, Steinherz PG, Tan CT, Heller
G and Murphy ML: Cardiac toxicity 4 to 20 years after completing
anthracycline therapy. JAMA. 266:1672–1677. 1991.
|
|
11
|
Wojnowski L, Kulle B, Schirmer M, et al:
NAD(P)H oxidase and multidrug resistance protein genetic
polymorphisms are associated with doxorubicin induced
cardio-toxicity. Circulation. 112:3754–3762. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tardi PG, Boman NL and Cullis PR:
Liposomal doxorubicin. J Drug Target. 4:129–140. 1996. View Article : Google Scholar
|
|
13
|
Kanter PM, Bullard GA, Ginsberg RA, et al:
Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC
D-99) versus free doxorubicin in beagle dogs. In Vivo. 7:17–26.
1993.PubMed/NCBI
|
|
14
|
Kanter PM, Klaich G, Bullard GA, et al:
Preclinical toxicology study of liposome encapsulated doxorubicin
(TLC D-99) given intraperitoneally to dogs. In Vivo. 8:975–982.
1994.PubMed/NCBI
|
|
15
|
Bally MB, Nayar R, Masin D, Hope MJ,
Cullis PR and Mayer LD: Liposomes with entrapped doxorubicin
exhibit extended blood residence times. Biochim Biophys Acta.
1023:133–139. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang X, Yang L, Chen Z and Shin DM:
Application of nanotechnology in cancer therapy and imaging. CA
Cancer J Clin. 58:97–110. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Symon Z, Peyser A, Tzemach D, et al:
Selective delivery of doxorubicin to patients with breast carcinoma
metastases by stealth liposomes. Cancer. 86:72–78. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harris L, Batist G, Belt R, et al:
Liposome-encapsulated doxorubicin compared with conventional
doxorubicin in a randomized multicenter trial as first-line therapy
of metastatic breast carcinoma. Cancer. 94:25–36. 2002. View Article : Google Scholar
|
|
19
|
Chan S, Davidson N, Juozaityte E, et al:
Phase III trial of liposomal doxorubicin and cyclophosphamide
compared with epirubicin and cyclophosphamide as first-line therapy
for metastatic breast cancer. Ann Oncol. 15:1527–1534. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Batist G, Ramakrishnan G, Rao CS, et al:
Reduced cardiotoxicity and preserved antitumor efficacy of
liposome-encapsulated doxorubicin and cyclophosphamide compared
with conventional doxorubicin and cyclophosphamide in a randomized,
multicenter trial of metastatic breast cancer. J Clin Oncol.
19:1444–1454. 2001.
|
|
21
|
Romero A, Rabinovich MG, Vallejo CT, et
al: Vinorelbine as first line chemotherapy for metastatic breast
carcinoma. J Clin Oncol. 12:336–341. 1994.PubMed/NCBI
|
|
22
|
Smith IE: Navelbine in combination
chemotherapy for advanced breast cancer. J Cancer Res Clin Oncol.
116:10521990.
|
|
23
|
Abeloff MD: Vinorelbine (Navelbine) in the
treatment of breast cancer: a summary. Semin Oncol. 22:1–4.
1995.PubMed/NCBI
|
|
24
|
Swain SM, Whaley FS, Gerber MC, et al:
Cardioprotection with dexrazoxane for doxorubicin containing
therapy in advanced breast cancer. J Clin Oncol. 15:1318–1332.
1997.PubMed/NCBI
|
|
25
|
Swain SM, Whaley FS, Gerber MC, et al:
Delayed administration of dexrazoxane provides cardioprotection for
patients with advanced breast cancer treated with
doxorubicin-containing therapy. J Clin Oncol. 15:1333–1340.
1997.
|
|
26
|
Legha SS, Benjamin RS, Mackay B, et al:
Reduction of doxorubicin cardiotoxicity by prolonged continuous
intravenous infusion. Ann Intern Med. 19:133–139. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Van Dalen EC, Michiels EM, Caron HN and
Kremer LC: Different anthracycline derivatives for reducing
cardiotoxicity in cancer patients. Cochrane Database Syst Rev.
5:CD0050062010.
|
|
28
|
Liemm AA, Appleyard MV, O’Neill MA, Hupp
TR, Chamberlain MP and Thompson AM: Doxorubicin and vinorelbine act
independently via p53 expression and p38 activation respectively in
breast cancer cell lines. Br J Cancer. 88:1281–1284. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Norris BI, Pritchard KI, James K, et al:
Phase III comparative study of vinorelbine combined with
doxorubicin versus doxorubicin alone in disseminated
metastatic/recurrent breast cancer. National Cancer Institute of
Canada Clinical Trials Group Study MA8. J Clin Oncol. 18:2385–2394.
2000.
|
|
30
|
Pawlicki MI, Rolski J, Zaluski J,
Siedlecki P, Ramlau C and Tomzak P: A phase II study of intravenous
navelbine and doxorubicin combination in previously untreated
advanced breast carcinoma. Oncologist. 7:205–209. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lorvidhaya VI, Kamnerdsupaphon P,
Chitapanarux I, et al: Combination of vinorelbine + doxorubicin in
advanced breast cancer. Gan To Kagaku Ryoho. 30:1131–1138.
2003.PubMed/NCBI
|
|
32
|
Ejlertsen B1, Mouridsen HT, Langkjer ST,
Andersen J, Sjöström J and Kjaer M: Scandinavian Breast Group Trial
(SBG9403): Phase III study of intravenous vinorelbine in
combination with epirubicin versus epirubicin alone in patients
with advanced breast cancer: a Scandinavian Breast Group Trial
(SBG9403). J Clin Oncol. 22:2313–2320. 2004. View Article : Google Scholar
|
